Muscle Training Induced Angiogenesis in COPD (COPDµvasc)

January 10, 2020 updated by: University Hospital, Montpellier

Impact of Exercise Training on Skeletal Muscle Capillary Maturation During Angiogenesis in COPD Patients

COPD patients experiment a peripheral muscle dysfunction which impact their exercise tolerance and health-related quality of life. The capillary to fiber interface is reduced and impact the exercise capacity of the patients. While the muscle capillary creation in response to exercise training is blunted in COPD patients, the maturation of the neo-capillaries could also be blunted and contribute to the impaired aniogionenesis in patients. Because the capillary maturation is a sensitive and dynamic process, only different modalities of exercise training and multiple time-points of measures would allow to capture this microvascular adaptation.

Aim of the study : Compare the muscle capillary maturation in response to training at 5 and 10 weeks, in sedentary healthy subject trained at the intensity of the ventilatory threshold (60-65% of VO2max), versus :- COPD patients trained at a similar intensity (60-65% of VO2max)- COPD patients trained at a similar absolute intensity (90% of VO2max).

Study Overview

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montpellier, France, 34295
        • Department of clinical Physiology - University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • COPD patients :
  • FEV1<80%pred.
  • non exacerbation during the past 4 weeks
  • no oxygen therapy, -

Healthy subjects:

  • <150min/week of moderate-to-vigorous physical activity,
  • Voorrips score <9

Exclusion Criteria:

  • Unstable comorbidity
  • Long term oxygen therapy or ventilation
  • Rehabilitation program during the past 12 months
  • nutritional supplementation during the past 4 weeks
  • allopurinol or N-acetylcystein during the past 4 weeks
  • long corticosteroid treatment during the past 6 months
  • hyperreactivity to xylocain
  • anticoagulant or platelet aggregation inhibitors treatment
  • participation to an other research study-pregnancy or impossibility to provide informed consent, ...

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: COPD Patients ~90% VO2max
Active Comparator: COPD patients ~60-65% VO2max
Placebo Comparator: healthy volunteers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Capillary-o-fiber ratio assessed by immunochemistry on a muscle biopsy of the vastus lateralis of the quadriceps
Time Frame: 5 weeks
5 weeks
Capillary-o-fiber ratio assessed by immunochemistry on a muscle biopsy of the vastus lateralis of the quadriceps
Time Frame: 10 weeks
10 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
quadriceps endurance
Time Frame: 5 weeks
5 weeks
quadriceps endurance
Time Frame: 10 weeks
10 weeks
Pericyte coverage of skeletal muscles capillaries assessed by immunostaining of a muscle biopsy of the vastus lateralis of the quadriceps
Time Frame: 5 weeks
5 weeks
Pericyte coverage of skeletal muscles capillaries assessed by immunostaining of a muscle biopsy of the vastus lateralis of the quadriceps
Time Frame: 10 weeks
10 weeks
Effect of the serum of COPD patients and SHS on pericyte morphology and in vitro
Time Frame: 10 weeks
10 weeks
Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vitro
Time Frame: 10 weeks
10 weeks
Effect of the serum of COPD patients and SHS on pericyte/endothelial cells interactions in vivo
Time Frame: 10 weeks
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Farés Gouzi, University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2014

Primary Completion (Actual)

April 1, 2016

Study Completion (Actual)

August 1, 2016

Study Registration Dates

First Submitted

January 10, 2014

First Submitted That Met QC Criteria

January 16, 2014

First Posted (Estimate)

January 20, 2014

Study Record Updates

Last Update Posted (Actual)

January 14, 2020

Last Update Submitted That Met QC Criteria

January 10, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 9224

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Muscular biopsy

3
Subscribe